Treatment with P6, a JAK inhibitor, represses tumor proliferation and pSTAT3 phosphorylation in EGFR-mutant cells (11–18, H1650, and H1975) but not in KRAS-mutant cells (H460). This evidence concerns the gene KRAS and neoplasm.